Related Experiment Video
Updated: May 16, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Emergency medicine pharmacists and sepsis management
Kyle A Weant1, Stephanie N Baker
1North Carolina Public Health Preparedness and Response, North Carolina Department of Public Health, Raleigh, NC 27699, USA. kaw9600@alumni.unc.edu
Purpose:
To describe the role that an emergency medicine (EM) clinical pharmacist has on the management of patients presenting to the emergency department (ED) with sepsis, severe sepsis, or septic shock.
Methods:
The clinical consultations documented by the EM pharmacists at an academic, teaching hospital over a 2-year period were retrospectively reviewed.
Results:
During the study period, a total of 585 consultations were provided by the EM pharmacists to 130 patients who presented to the ED with a diagnosis of sepsis, severe sepsis, or septic shock. Dosing recommendations were the most frequent consultations provided (n = 309, 53%), followed by the addition of appropriate empiric antibiotics (n = 131, 22%) and medication preparation (n = 108, 19%). Antibiotics (n = 307, 83%) and vasopressors (n = 31, 8%) were the medication classes regularly involved in EM pharmacist consultations. Vancomycin (n = 90, 28%) and norepinephrine (n = 15, 48%) were the most common agents involved in these consultations.
Conclusion:
A clinical EM pharmacist has multiple roles in the early management of patients presenting with sepsis, severe sepsis, or septic shock in the ED. Most commonly, they have a role in optimizing empiric antibiotic selection and dosing; thereby ensuring adequate antimicrobial coverage in this complex patient population.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmaceutical Poisoning: Potential Scenarios
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Poisoning: Treatment Strategies
